[1] Ganem D,Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med,2004,350(11):1118-1129. [2] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [3] Zoulin F,Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology,2009,137(5):1593-608. [4] Yeh CT,Chien RN,Chu CM,et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology,2000,31(6):1318-1326. [5] Chien RN. Yeh CT,Wang PN,et al. Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract,2004,58(11):1088-1091. [6] Gerolami R,Bourliere M,Colson P,et al. Unusual selection of rtA181V HBV mutants crossresistant to adefovir following prolonged lamivudine monotherapy:report of two cases. Antivir Ther,2006,11(8):1103-1106. [7] Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med,2005,352(26):2673-2681. [8] Yeon JE,Yoo W,Hong SP,et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut,2006,55(10):1488-1495. [9] Lai CL,Gane E,Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357(25):2576-2588. [10] 赵攀,钟彦伟,徐东平. 5例应用恩替卡韦治疗的慢性HBV感染者发生HBV逆转录酶区单独A181位点突变的分析. 临床肝胆病杂志,2011,27(3):289-291. [11] Warner N,Locarnini S. The Antiviraldrug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology,2008,48(1):88-98. [12] 徐东平,刘妍,成军,等. 340例慢性乙型肝炎患者乙型肝炎病毒多位点耐药相关突变分析. 中华肝脏病杂志,2008,16(10):735-738. [13] 吴云海,吴云萍,张晓棠,等. HBV反转录酶A181位点变异与临床耐药的关系. 肝脏,2009,14(2):105-107. [14] Villet S,Pichoud C,Billioud G,et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol,2008,48(5):747-755. [15] 吴珍萍,韩涛,高英堂,等. 拉米夫定耐药后阿德福韦酯治疗应答欠佳患者乙型肝炎病毒耐药变异模式. 中华肝脏病杂志,2010,18(5):498-501. [16] Yatsuji H,Noguchi C,Hiraga N,et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother,2006,50(11):3867-3874. [17] 李新艳,尹有宽,张继明,等. 阿德福韦耐药乙型肝炎病毒毒株生物学特性的研究. 中华传染病杂志,2009,27(8):478-483. [18] Kim JH,Jung YK,Joo MK,et al. Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci,2010,25(2):257-264. [19] 王春亚,钟彦伟,刘杰,等.HBV逆转录酶区M204位点单独突变患者与M204+A181T联合突变患者临床特征的比较.实用肝脏病杂志,2010,13(4):260-262. [20] 王春亚,钟彦伟,杨昊臻,等. HBV逆转录酶区N236T突变与A181T突变患者的临床特征的比较. 实用医院临床杂志,2010,7(4):47-48. [21] Qi X,Zhu Y,Curtis M,et al. In vitro cross-resistance analysis of the HBV polymerase mutation A181V. J Hepatol,2005,42(Suppl 2):194-195. [22] Lai MW,Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther,2008,13:875-879. [23] 郑佳佳,蒋素贞,张婷,等. HBV sW172*耐药突变体引起的截短蛋白胞内堆积可能通过ER stress通路参与致肝癌机制.南京:第15届全国病毒性肝炎及肝病学术会议,中华医学会,2011,100-101. [24] Patterson SJ,George J,Strasser SI,et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut,2011,60(2):247-254. [25] Kurashige N,Ohkawa K,Hiramatsu N,et al. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir Ther,2009,14(6):873-877. [26] Choe WH,Hong SP,Kim BK,et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther,2009,14(7):985-993. [27] European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B.J Hepatol,2009,50(2):227-242. [28] 王春亚,钟彦伟,刘杰,等. HBV 逆转录酶区A181T突变的临床意义. 军医进修学院学报,2010,31(11):1125-1126. |